Sarepta Therapeutics (SRPT) Cash & Current Investments (2010 - 2026)

Sarepta Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $405.6 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 22.42% year-over-year to $405.6 million in Q1 2026; TTM through Mar 2026 was $405.6 million, a 22.42% decrease from a year earlier, with the FY2025 full-year figure at $939.6 million, down 14.26% from the prior year.
• Cash & Current Investments declined to $405.6 million in Q1 2026 per SRPT's latest filing, from $939.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $2.1 billion in Q3 2022 and bottomed at $242.5 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $1.5 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Cash & Current Investments sank 86.01% in 2024 and surged 164.96% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $2.0 billion in 2022, then dropped by 15.74% to $1.7 billion in 2023, then slumped by 34.62% to $1.1 billion in 2024, then decreased by 14.26% to $939.6 million in 2025, then sank by 56.84% to $405.6 million in 2026.
• Per Business Quant, the three latest SRPT Cash & Current Investments figures stand at $405.6 million (Q1 2026), $939.6 million (Q4 2025), and $642.5 million (Q3 2025).